跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-05AI 评分45

Vaxcyte肺炎球菌疫苗VAX-31三期试验成功,股价单日上涨35%

Vaxcyte's pneumococcal vaccine succeeds in Phase 3, stock surges

AI 导读

Vaxcyte宣布其实验性肺炎球菌疫苗VAX-31在三期临床试验中达到关键终点。受此消息影响,该公司股票代码PCVX周一早盘股价上涨35%。

正文

Vax­cyte’s shares $PCVX jumped 35% Mon­day morn­ing af­ter the com­pa­ny an­nounced that its ex­per­i­men­tal pneu­mo­coc­cal vac­cine VAX-31 met its key end­points in a Phase 3 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news